Recently, results from the SOLAR-1 phase III randomized controlled trial (NCT02437318) indicated a significant improvement in Progression Free Survival (PFS) from the addition of alpelisib to the fulvestrant treatment in HER2 negative, Hormonal Receptors (HR) positive Breast Cancers patients who harbored a PIK3CA mutation accessed either using tissue or plasma. Here, ERBB2 is linked to breast carcinoma.